Company news
Amplia Therapeutics Ltd. (ASX:ATX) news
Amplia Therapeutics Ltd. news releases on 6ix. Latest, Aug 3, 2026: Amplia signs Collaboration and Supply Agreement with Lilly
Press releases & updates
Amplia signs Collaboration and Supply Agreement with Lilly
August 3, 2026
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
July 31, 2026
Amplia Announces Publication of New FAK Inhibitor Patent Application
July 9, 2026
Amplia Announces Appointment of Brett Carter to Board
July 7, 2026
Amplia Announces Changes to Board’s Leadership Roles
July 6, 2026
Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
June 22, 2026
Preliminary Final Report and Annual Report YE 31 March 2026
May 28, 2026
Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
May 19, 2026
Amplia Launches First Stage of Pivotal Narmafotinib Trial
May 18, 2026
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
May 8, 2026
Amplia and ANZGOG announce Ovarian Cancer Study
May 7, 2026
Accent Trial Mature Data Presented at International Conference
April 22, 2026
Amplia Therapeutics Halts Recruitment in AMPLICITY Trial
April 6, 2026
Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
March 23, 2026
Amplia Reports Improved Responses & Survival in ACCENT trial
March 22, 2026
Trading Halt
March 19, 2026
Pause in Trading
March 18, 2026
Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th
March 11, 2026
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
March 9, 2026
Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
February 11, 2026
Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
January 30, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
NARMAFOTINIB Large-Scale Manufactre Complete
January 22, 2026
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
January 12, 2026
Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
December 23, 2025
Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
December 19, 2025
Additional Confirmed Response Reported as Part of Amplia Investor Presentation
December 12, 2025
Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th
December 8, 2025
Key Narmafotinib Patent Granted in the U.S.
December 3, 2025
Half Yearly Report and Accounts
November 27, 2025
Positive Response from US FDA to Amplia's Type D Meeting
November 19, 2025
Amplia Receives R&D Tax Rebate Totalling $3.77 Million
October 27, 2025
FIRST PATIENT DOSED IN NEW PANCREATIC CANCER TRIAL
September 3, 2025
Amplia Share Purchase Plan Raises $2.65 Million
August 25, 2025
Positive ACCENT Trial Topline Data Released
August 5, 2025
Capital Raising Presentation
July 23, 2025
Amplia announces A$25m Placement and Launches A$2.5m SPP
July 23, 2025
Second Complete Response in ACCENT Pancreatic Cancer Trial
June 18, 2025
PATHOLOGICAL COMPLETE RESPONSE RECORDED IN PATIENT FROM ACCENT CANCER TRIAL
June 16, 2025
Pathological Complete Response in Pancreatic Cancer Trial
June 15, 2025
Preliminary Final Report and Annual Report YE 31 March 2025
May 30, 2025
ACCENT Trial Achieves Superiority over Chemotherapy Alone
May 14, 2025
Completion of Recruitment of ACCENT Trial
January 30, 2025
Security Class Reinstatement to Quotation - ATXOA
December 23, 2024
App 4D and Financial Report Half Year ended 30 Sep 2024
November 27, 2024
Security Class Suspension from Quotation
November 24, 2024
Amplia Successfully Completes Institutional Offer
October 31, 2024
Capital Raise Presentation
October 30, 2024
Amplia to Raise up to $13m for ACCENT and US Trials
October 30, 2024
Interim Data From Accent Pancreatic Cancer Trial
October 30, 2024